2025 Q3 -tulosraportti
79 päivää sitten23 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
7 336
Myynti
Määrä
21 638
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 045 | - | - | ||
| 650 | - | - | ||
| 500 | - | - | ||
| 5 987 | - | - | ||
| 3 000 | - | - |
Ylin
0,985VWAP
Alin
0,964VaihtoMäärä
0,1 91 628
VWAP
Ylin
0,985Alin
0,964VaihtoMäärä
0,1 91 628
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 98 964 | 98 964 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 98 964 | 98 964 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 20.3. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 19.11.2025 | |
| 2025 Q2 -tulosraportti | 15.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| 2024 Q4 -tulosraportti | 20.3.2025 | |
| 2024 Q3 -tulosraportti | 14.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 t sittenRUO revenue saves the financial report, now that hospitals refrain from buying the product. Remarkable development. 3D otherwise talked a lot about the "recurring orders" that would secure the future, but apparently it's only sales to research that drives limited growth. I don't think 3D comments on this development, but I think others should be aware that management itself "notes" the RUO revenue and it cannot be equated with normal revenue. It embellishes the result, but also reveals a business that is declining more than the headline reveals when the "strong" momentum is described by management.
·2 t sittenThat RUO still takes up so much space and further confirms that there is no significant and real growth. The optimists are lying to themselves. And as BP communicates, they almost seem to deliberately feed those lies. I am now becoming more and more concerned about BP because there is so little real demand for ngal. And where I long believed that a day would surely come when the optimists would send the stock on one of the sudden upturns it has taken before, I now believe less and less in that possibility. I mostly believe in a slow painful death- ·3 t sitten · MuokattuJust 300.000 kr from a result below guidance. Revenue increases by 11 % in 2025 and the EBIT loss increases by approx. 8 %. Should BP really bet on a new market in India @3D now that BP is riding the big wave? Expects a growth of +20 % in 2026 and again BP tries with an assessment that growth will only come late in 2026. Wasn't it the same old story from 2025, where growth didn't materialize and it resulted in 2 downgrades instead. The cash reserves show that there is operation for approx. 7-8 months from January 1, 2026, until the cash reserves need to be refilled again. The clock is ticking.
- ·4 t sitten · MuokattuThere is a webcast at 2 PM today, regarding the financial report that was released yesterday. Registration required. https://hca.videosync.fi/2026-02-06-investor-prsentation/register
·4 t sittenPreliminary figures for 2025 + GUIDANCE for 2026 were released last night. They clearly follow their plan and the guidance for 2026 is an improvement compared to 2025. Figures were not expected until March 24 with the final financial report, but I interpret this much earlier release as them being happy and proud of the development, and therefore figures are presented already now. Extremely pleasing Bioporto Q4: Presents preliminary figures and provides expectations for 2026 today at 06:34 ∙ MarketWire The biotech company Bioporto released preliminary figures for its fourth quarter on Thursday evening and presented expectations for the new year. In a company announcement from Bioporto, it states that the company sold for DKK 11.6 million in the fourth quarter, compared to DKK 7.9 million in the same quarter the year before. A large part of the revenue is attributable to the sale of the NGAL kidney test for research use. I am satisfied that the preliminary results for 2025 live up to our latest guidance. We continue to execute on our "Forward"-strategy and grow the NGAL business. We experienced very strong top-line growth in NGAL in the fourth quarter of 2025, which was helped by a larger order from our strategic distributor, while also showing very strong growth in the USA from RUO (Research Use Only), says Carsten Buhl, CEO of Bioporto, in the announcement. In adjusted operations, EBITDA, the deficit also shrinks to approx. DKK 13.7 million from a deficit of DKK 19.4 million in the same period the year before. In 2026, Bioporto expects to generate revenue of DKK 48-58 million, of which DKK 33-42 million will come from the NGAL kidney test. In adjusted operations, EBITDA, a loss of between DKK 50-60 million is expected.·3 t sittenGrowth How is the liquidity? A loss of 50-60 million DKK. Isn't that a larger loss than their liquid reserves can cover?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
79 päivää sitten23 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sittenRUO revenue saves the financial report, now that hospitals refrain from buying the product. Remarkable development. 3D otherwise talked a lot about the "recurring orders" that would secure the future, but apparently it's only sales to research that drives limited growth. I don't think 3D comments on this development, but I think others should be aware that management itself "notes" the RUO revenue and it cannot be equated with normal revenue. It embellishes the result, but also reveals a business that is declining more than the headline reveals when the "strong" momentum is described by management.·2 t sittenThat RUO still takes up so much space and further confirms that there is no significant and real growth. The optimists are lying to themselves. And as BP communicates, they almost seem to deliberately feed those lies. I am now becoming more and more concerned about BP because there is so little real demand for ngal. And where I long believed that a day would surely come when the optimists would send the stock on one of the sudden upturns it has taken before, I now believe less and less in that possibility. I mostly believe in a slow painful death
- ·3 t sitten · MuokattuJust 300.000 kr from a result below guidance. Revenue increases by 11 % in 2025 and the EBIT loss increases by approx. 8 %. Should BP really bet on a new market in India @3D now that BP is riding the big wave? Expects a growth of +20 % in 2026 and again BP tries with an assessment that growth will only come late in 2026. Wasn't it the same old story from 2025, where growth didn't materialize and it resulted in 2 downgrades instead. The cash reserves show that there is operation for approx. 7-8 months from January 1, 2026, until the cash reserves need to be refilled again. The clock is ticking.
- ·4 t sitten · MuokattuThere is a webcast at 2 PM today, regarding the financial report that was released yesterday. Registration required. https://hca.videosync.fi/2026-02-06-investor-prsentation/register
- ·4 t sittenPreliminary figures for 2025 + GUIDANCE for 2026 were released last night. They clearly follow their plan and the guidance for 2026 is an improvement compared to 2025. Figures were not expected until March 24 with the final financial report, but I interpret this much earlier release as them being happy and proud of the development, and therefore figures are presented already now. Extremely pleasing Bioporto Q4: Presents preliminary figures and provides expectations for 2026 today at 06:34 ∙ MarketWire The biotech company Bioporto released preliminary figures for its fourth quarter on Thursday evening and presented expectations for the new year. In a company announcement from Bioporto, it states that the company sold for DKK 11.6 million in the fourth quarter, compared to DKK 7.9 million in the same quarter the year before. A large part of the revenue is attributable to the sale of the NGAL kidney test for research use. I am satisfied that the preliminary results for 2025 live up to our latest guidance. We continue to execute on our "Forward"-strategy and grow the NGAL business. We experienced very strong top-line growth in NGAL in the fourth quarter of 2025, which was helped by a larger order from our strategic distributor, while also showing very strong growth in the USA from RUO (Research Use Only), says Carsten Buhl, CEO of Bioporto, in the announcement. In adjusted operations, EBITDA, the deficit also shrinks to approx. DKK 13.7 million from a deficit of DKK 19.4 million in the same period the year before. In 2026, Bioporto expects to generate revenue of DKK 48-58 million, of which DKK 33-42 million will come from the NGAL kidney test. In adjusted operations, EBITDA, a loss of between DKK 50-60 million is expected.·3 t sittenGrowth How is the liquidity? A loss of 50-60 million DKK. Isn't that a larger loss than their liquid reserves can cover?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
7 336
Myynti
Määrä
21 638
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 045 | - | - | ||
| 650 | - | - | ||
| 500 | - | - | ||
| 5 987 | - | - | ||
| 3 000 | - | - |
Ylin
0,985VWAP
Alin
0,964VaihtoMäärä
0,1 91 628
VWAP
Ylin
0,985Alin
0,964VaihtoMäärä
0,1 91 628
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 98 964 | 98 964 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 98 964 | 98 964 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 20.3. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 19.11.2025 | |
| 2025 Q2 -tulosraportti | 15.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| 2024 Q4 -tulosraportti | 20.3.2025 | |
| 2024 Q3 -tulosraportti | 14.11.2024 |
2025 Q3 -tulosraportti
79 päivää sitten23 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 20.3. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 19.11.2025 | |
| 2025 Q2 -tulosraportti | 15.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| 2024 Q4 -tulosraportti | 20.3.2025 | |
| 2024 Q3 -tulosraportti | 14.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sittenRUO revenue saves the financial report, now that hospitals refrain from buying the product. Remarkable development. 3D otherwise talked a lot about the "recurring orders" that would secure the future, but apparently it's only sales to research that drives limited growth. I don't think 3D comments on this development, but I think others should be aware that management itself "notes" the RUO revenue and it cannot be equated with normal revenue. It embellishes the result, but also reveals a business that is declining more than the headline reveals when the "strong" momentum is described by management.·2 t sittenThat RUO still takes up so much space and further confirms that there is no significant and real growth. The optimists are lying to themselves. And as BP communicates, they almost seem to deliberately feed those lies. I am now becoming more and more concerned about BP because there is so little real demand for ngal. And where I long believed that a day would surely come when the optimists would send the stock on one of the sudden upturns it has taken before, I now believe less and less in that possibility. I mostly believe in a slow painful death
- ·3 t sitten · MuokattuJust 300.000 kr from a result below guidance. Revenue increases by 11 % in 2025 and the EBIT loss increases by approx. 8 %. Should BP really bet on a new market in India @3D now that BP is riding the big wave? Expects a growth of +20 % in 2026 and again BP tries with an assessment that growth will only come late in 2026. Wasn't it the same old story from 2025, where growth didn't materialize and it resulted in 2 downgrades instead. The cash reserves show that there is operation for approx. 7-8 months from January 1, 2026, until the cash reserves need to be refilled again. The clock is ticking.
- ·4 t sitten · MuokattuThere is a webcast at 2 PM today, regarding the financial report that was released yesterday. Registration required. https://hca.videosync.fi/2026-02-06-investor-prsentation/register
- ·4 t sittenPreliminary figures for 2025 + GUIDANCE for 2026 were released last night. They clearly follow their plan and the guidance for 2026 is an improvement compared to 2025. Figures were not expected until March 24 with the final financial report, but I interpret this much earlier release as them being happy and proud of the development, and therefore figures are presented already now. Extremely pleasing Bioporto Q4: Presents preliminary figures and provides expectations for 2026 today at 06:34 ∙ MarketWire The biotech company Bioporto released preliminary figures for its fourth quarter on Thursday evening and presented expectations for the new year. In a company announcement from Bioporto, it states that the company sold for DKK 11.6 million in the fourth quarter, compared to DKK 7.9 million in the same quarter the year before. A large part of the revenue is attributable to the sale of the NGAL kidney test for research use. I am satisfied that the preliminary results for 2025 live up to our latest guidance. We continue to execute on our "Forward"-strategy and grow the NGAL business. We experienced very strong top-line growth in NGAL in the fourth quarter of 2025, which was helped by a larger order from our strategic distributor, while also showing very strong growth in the USA from RUO (Research Use Only), says Carsten Buhl, CEO of Bioporto, in the announcement. In adjusted operations, EBITDA, the deficit also shrinks to approx. DKK 13.7 million from a deficit of DKK 19.4 million in the same period the year before. In 2026, Bioporto expects to generate revenue of DKK 48-58 million, of which DKK 33-42 million will come from the NGAL kidney test. In adjusted operations, EBITDA, a loss of between DKK 50-60 million is expected.·3 t sittenGrowth How is the liquidity? A loss of 50-60 million DKK. Isn't that a larger loss than their liquid reserves can cover?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
7 336
Myynti
Määrä
21 638
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 045 | - | - | ||
| 650 | - | - | ||
| 500 | - | - | ||
| 5 987 | - | - | ||
| 3 000 | - | - |
Ylin
0,985VWAP
Alin
0,964VaihtoMäärä
0,1 91 628
VWAP
Ylin
0,985Alin
0,964VaihtoMäärä
0,1 91 628
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 98 964 | 98 964 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 98 964 | 98 964 | 0 | 0 |